ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib

被引：1
|
作者：
Stubbs, Matthew C. [1 ]
Pusey, Michelle [1 ]
Wen, Xiaoming [1 ]
Drake, Katherine [1 ]
Zolotarjova, Nina [1 ]
Smith, Amanda [1 ]
Covington, Maryanne [1 ]
Zhang, Guofeng [1 ]
Macarron, Ricardo [2 ]
Kim, Sunkyu [1 ]
机构：
[1] Incyte Res Inst, Wilmington, DE USA
[2] Incyte, Wilmington, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181055
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib
    Saha, Chandan
    Harrison, Claire
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 583 - 595
  • [22] Development of a new class of ALK2 inhibitor for the study of the most aggressive paediatric brain cancer, DIPG
    Hudson, Liam
    Woodward, Hannah
    Hoelder, Swen
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [23] Discovery of conformationally constrained ALK2 inhibitors for the treatment of Diffuse Intrinsic Pontine Glioma ( DIPG)
    Smil, David
    Gonzalez-Alvarez, Hector
    Ensan, Deeba
    Wong, Jong Fu
    Cros, Julien
    Hoffer, Laurent
    Kiyota, Taira
    Wilson, Brian J.
    Zepeda-Velazquez, Carlos A.
    Aman, Ahmed
    Isaac, Methvin B.
    Xin, Tao
    Bullock, Alex N.
    Sampson, Peter B.
    Al-awar, Rima
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (12)
  • [24] Rational design of ALK2 small molecule inhibitors for treatment of fibrodysplasia ossificans progressiva (FOP)
    Luo, Yun
    Alsamarah, Abdelaziz
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [25] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    N Jaekel
    G Behre
    A Behning
    C Wickenhauser
    T Lange
    D Niederwieser
    H K Al-Ali
    Bone Marrow Transplantation, 2014, 49 : 179 - 184
  • [26] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    Jaekel, N.
    Behre, G.
    Behning, A.
    Wickenhauser, C.
    Lange, T.
    Niederwieser, D.
    Al-Ali, H. K.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 179 - 184
  • [27] Recent advances in JAK2 inhibition for the treatment of myelofibrosis
    Rippel, Noa
    Kremyanskaya, Marina
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (09) : 1175 - 1186
  • [28] Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis
    Bhagwat, Neha
    Keller, Matthew D.
    Rampal, Raajit K.
    Shank, Kaitlyn
    de Stanchina, Elisa
    Rose, Kristine
    Amakye, Dereck
    Levine, Ross L.
    BLOOD, 2013, 122 (21)
  • [29] A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation
    Wang, Chia-Yu
    Melgar-Bermudez, Emiliano
    Welch, Diana
    Dagbay, Kevin B.
    Bhattacharya, Seemana
    Lema, Evan
    Daman, Tyler
    Sierra, Olivia
    Todorova, Radina
    Drame, Papa Makhtar
    Grenha, Rosa
    Fisher, Ffolliott M.
    Grayson, Dena
    Lerner, Lorena
    Cadena, Samuel M.
    Seehra, Jasbir
    Lachey, Jennifer
    AMERICAN JOURNAL OF HEMATOLOGY, 2025,
  • [30] Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).
    Bose, Prithviraj
    Mohan, Sanjay
    Oh, Stephen
    Gotlib, Jason R.
    Ritchie, Ellen K.
    Shimomura, Taizo
    Ali, Haris
    Boyer, Francoise
    Guglielmelli, Paola
    Hunter, Anthony
    Lamothe, Betty
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Palandri, Francesca
    Takeuchi, Masahiro
    Kiladjian, Jean-Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345